Celgene just lost one of the most important drugs in its research pipeline to a late-stage clinical trial blowup.
The drug is mongersen, a key component in Celgene’s burgeoning immunology and inflammation franchise. On Thursday, a phase 3 study of mongersen in Crohn’s disease was halted prematurely following a finding of clinical futility by independent monitors, the company said.
Many people will not know the financial impact of Celgene stopping two trials for Crohn’s disease. Celgene has announced that info in an SEC filing. http://alphastreet.com/bce290d5
Comments are closed.